TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate TTX MC 138

This IPO Is Just $4, Should You Buy, Transcode Therapeutics RNAZ Going Public May 14Подробнее

TransCode Therapeutics; Oligonucleotide Therapeutics SocietyПодробнее

RNAZ Stock Analysis! Transcode Therapeutics Stock News! $RNAZ 9/27/2023Подробнее

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in TNBCПодробнее

266 Treating Cancer with DideoxynucleosidesПодробнее

Bladder Cancer & Intravesical Therapy - CTR Coding Break (December 2020)Подробнее

Revolutionizing Cancer Treatment: The Promising Era of VaccinesПодробнее

TransCode Therapeutics: TTX MC138 AnimationПодробнее

RNAZ Stock-Transcode Therapeutics Inc Stock Breaking News Today | RNAZ Stock Price Prediction | RNAZПодробнее

Interventional Immunotherapy: Transforming the Treatment of Solid TumorsПодробнее

Progress Report I - Péter TajtiПодробнее

2024 Tandem Meetings: Mortimer M. Bortin LectureПодробнее

MPCCC Precision Oncology Seminar: Professor Tony PurcellПодробнее

Future developments in the treatment of prostate cancerПодробнее

TAILORx: Phase 3 trial validating a 21-gene expression assay in breast cancerПодробнее

Optimizing the Management of Metastatic TNBC: Diagnostics, Treatments and Hope for the FutureПодробнее

Explanatory Overview: GCP Training Mutual Recognition facilitated by TransCelerateПодробнее

2022 RDCA-DAP Workshop: Case Study 1, Transplant Therapeutics Consortium (TTC)Подробнее

Webinar: Predictive Pre Clinical Oncology Studies Using Patient-Derived Xenograft PlatformsПодробнее